Acute Leukemia
Conditions
Brief summary
Evaluation the efficacy and safety of the combination of injectable bevacizumab, low-intensity chemotherapy, and venula in the treatment of newly diagnosed CD19+mixed phenotype acute leukemia in adults
Interventions
DRUGBevacizumab
Evaluation of the efficacy and safety of the combination of injectable bevacizumab, low-intensity chemotherapy, and venula in the treatment of newly diagnosed CD19+mixed phenotype acute leukemia in adults
Sponsors
Ruijin Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Patients fully understand this study, voluntarily participate and sign an informed consent form (ICF); 2. Age: 18-75 years old (including boundary values of 18 and 75); 3. Clinically diagnosed adult Mixed Phenotype Acute Leukemia (WHO 2016 criteria) patients with CD19 positivity
Exclusion criteria
The subject's previous history of anti-tumor treatment meets one of the following conditions: 1. Individuals who have previously received bevacizumab 2. Individuals who have received CAR-T therapy or other gene modified cell therapies prior to screening; 3. Within 5 half lives of the first use of the investigational drug, having received anti-tumor treatment including surgery, chemotherapy, targeted therapy, or participating in other clinical trials and receiving clinical trial medication;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Negative conversion rate of evaluable residual lesions (MRD) | 1 year |
Countries
China
Contacts
Primary ContactWang Chun
Outcome results
None listed